An anti-aging composition and its application

By combining γ-aminobutyric acid with zinc sulfate and adenine, synergistic compounding technology inhibits fibroblast aging at low doses, the skin allergic reaction caused by γ-aminobutyric acid at high concentrations was solved, and the skin was achieved Significant anti-aging effect and improved comfort.

CN118845509BActive Publication Date: 2024-12-03HUAXI BIOTECHNOLOGY (XIANGTAN) CO LTD +1
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202411319585.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03
Estimated Expiration
2044-09-23

AI Technical Summary

Technical Problem

Gamma-aminobutyric acid may cause skin allergic reactions at higher concentrations, and the prior art has failed to effectively resolve the adverse reactions caused by its use in skin care products.

Method used

Combining γ-aminobutyric acid with zinc sulfate and adenine can inhibit fibroblast aging at low addition amounts by synergistically combining it to promote collagen expression, reduce the use of γ-aminobutyric acid, and reduce skin irritation.

Benefits of technology

It significantly inhibits fibroblast aging, promotes collagen expression, reduces the stimulating response of γ-aminobutyric acid to the skin, increases the comfort of use, and provides significant anti-aging effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118845509B_ABST
    Figure CN118845509B_ABST
Patent Text Reader

Abstract

The present invention discloses an anti-aging composition and its application, wherein the anti-aging composition comprises γ-aminobutyric acid, zinc sulfate and adenine. The present invention can inhibit the aging of human fibroblasts and promote the expression of collagen through the synergistic compounding of γ-aminobutyric acid, zinc sulfate and adenine, and has a synergistic effect. The anti-aging composition provided by the present invention can exert a significant anti-aging effect using a low dose of γ-aminobutyric acid. In actual use, the addition amount of γ-aminobutyric acid can be reduced through the compounding of the components of the composition, the skin irritation and allergic reaction of γ-aminobutyric acid can be reduced, and the comfort of use can be increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an anti-aging composition and also to application of the composition, belonging to the technical field of anti-aging. Background Art

[0002] Gamma-aminobutyric acid (GABA) is a naturally occurring non-protein amino acid that is widely found in animal brains and natural plants. It is not only an active substance synthesized by the human body and widely distributed in various organs, but also has a variety of physiological functions, including regulating arrhythmias, improving lipid metabolism, preventing arteriosclerosis, regulating hormone secretion, and preventing skin aging. In terms of skin care, the effects of GABA are mainly reflected in the following aspects:

[0003] Anti-aging: With age, the GABA content in the body decreases, causing neurons to not relax for a long time, which may cause excessive contraction of skin muscles and the formation of wrinkles. GABA can stimulate fibroblasts to synthesize collagen and hyaluronic acid, promote dermal remodeling, anti-oxidation and help repair the epidermal barrier, thereby reducing the formation of wrinkles and making the skin more elastic.

[0004] Repair and soothing: GABA has a calming and soothing effect, can regulate skin sensitivity, and reduce the skin's response to external stimuli. It is suitable for sensitive skin and tired skin. It can also promote nighttime skin repair and relieve fatigue, helping the skin return to a healthy state.

[0005] Antioxidant: As an antioxidant, GABA can help protect against free radical damage, slowing down the skin aging process and making the skin younger and more elastic. It is suitable for use at night to help promote nighttime skin repair and relieve fatigue.

[0006] Although GABA has good anti-aging effects, γ-aminobutyric acid at higher concentrations may stimulate mast cells to release histamine, leading to increased capillary permeability, smooth muscle contraction, and increased glandular secretion, thereby inducing or aggravating skin allergy symptoms and causing skin allergic reactions.

[0007] There are many reports on skin care compositions containing γ-aminobutyric acid, such as CN116987142A, CN114470005A, CN114515253A, CN114681368A, etc. However, these prior arts only propose that γ-aminobutyric acid and different combinations of ingredients have different skin care effects, and do not involve the above-mentioned defects of γ-aminobutyric acid during use. Summary of the invention

[0008] The present invention creatively discovered that the combination of γ-aminobutyric acid with zinc sulfate and adenine has a synergistic effect, and can significantly inhibit fibroblast aging and promote collagen expression at a low addition amount, thus exerting a significant anti-aging effect. Based on this, the dosage of γ-aminobutyric acid can be reduced, thereby avoiding the adverse reactions to the skin caused by the use of γ-aminobutyric acid at a higher concentration.

[0009] The invention provides an anti-aging composition, which comprises gamma-aminobutyric acid, zinc sulfate and adenine.

[0010] In the anti-aging composition, the mass ratio of the gamma-aminobutyric acid, zinc sulfate and adenine is 40-220:0.04-0.25:0.08-7.

[0011] In the above anti-aging composition, the mass ratio of the γ-aminobutyric acid, zinc sulfate and adenine is preferably 50-200: 0.05-0.2: 0.1-5.

[0012] The present invention also provides the use of the anti-aging composition in preparing a product for promoting collagen production.

[0013] Furthermore, in the above application, the collagen includes type III collagen.

[0014] Furthermore, in the above application, the product that promotes collagen production includes skin care products, medicines or medical device products.

[0015] The present invention also provides the use of the anti-aging composition in preparing a product for inhibiting fibroblast aging.

[0016] Furthermore, in the above application, the product that inhibits fibroblast aging includes skin care products, medicines or medical device products.

[0017] The present invention also provides a skin care product, comprising the anti-aging composition.

[0018] In the above skin care product, the content of the γ-aminobutyric acid in the skin care product is 10 to 1000 mg / L.

[0019] In the above skin care product, the content of zinc sulfate in the skin care product is 0.1-10 mg / L.

[0020] In the above skin care product, the content of adenine in the skin care product is 0.1-10 mg / L.

[0021] The above-mentioned skin care products further include active ingredients and / or auxiliary materials acceptable in the field of skin care products.

[0022] The present invention has the following beneficial effects:

[0023] 1. The anti-aging composition provided by the present invention can promote the expression of collagen III (COL III) in human fibroblasts through the synergistic combination of γ-aminobutyric acid, zinc sulfate and adenine, and can promote the improvement of human fibroblast (HFF) aging, inhibit the aging of human fibroblasts, and has a synergistic effect.

[0024] 2. The anti-aging composition provided by the present invention can promote the expression of collagen, especially the expression of type III collagen, through the synergistic combination of γ-aminobutyric acid, zinc sulfate and adenine, and has a synergistic effect.

[0025] 3. The anti-aging composition provided by the present invention can exert a significant anti-aging effect using a low dose of γ-aminobutyric acid. In actual use, the amount of γ-aminobutyric acid added can be reduced by compounding the various components of the composition, thereby reducing the skin irritation and allergic reactions of γ-aminobutyric acid and increasing the comfort of use.

[0026] 4. The anti-aging composition provided by the present invention has simple ingredients and readily available raw materials, does not require a complicated preparation process, has low cost, and is easy to promote and commercialize. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the immunofluorescence quantitative result of the DMEM blank control group and Example 3 on the collagen III protein level. DETAILED DESCRIPTION

[0028] The following is a description of exemplary embodiments of the present invention, including various details of the embodiments of the present invention to aid understanding, which should be considered as merely exemplary. Therefore, it should be appreciated by those of ordinary skill in the art that various changes and modifications may be made to the embodiments described herein without departing from the scope and spirit of the present invention. Likewise, for clarity and simplicity, descriptions of well-known functions and structures are omitted in the following description.

[0029] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those commonly understood by those skilled in the art. Although similar or identical methods and materials as those described herein may be used in experiments or practical applications, the present invention still describes the materials and methods below. In the event of a conflict, the present specification, including definitions, shall prevail.

[0030] The present invention relates to a composition, and the "composition" can achieve the effects of the present invention, and the "composition" includes but is not limited to using the components simultaneously or sequentially. The "simultaneous use" includes using them together in the same preparation or using them separately in different preparations. The "sequential use" includes using them sequentially in different preparations, and there is no restriction on the order of sequential use.

[0031] The present invention provides an anti-aging composition, which includes gamma-aminobutyric acid, zinc sulfate and adenine. Experimental verification shows that the combination of the three can significantly inhibit the aging of human fibroblasts, significantly promote the expression of collagen, and show a significant synergistic effect. The use of this composition can reduce the dosage of gamma-aminobutyric acid and reduce the adverse stimulation to the skin caused by excessive dosage of gamma-aminobutyric acid.

[0032] In a specific embodiment of the present invention, the anti-aging composition contains 40 to 220 parts by mass of γ-aminobutyric acid, for example 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220 parts, etc., preferably 50 to 200 parts by mass.

[0033] In a specific embodiment of the present invention, the anti-aging composition contains 0.04 to 0.25 parts by mass of zinc sulfate, for example, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, etc., preferably 0.05 to 0.2 parts by mass.

[0034] In a specific embodiment of the present invention, the anti-aging composition contains 0.08 to 7 parts by mass of adenine, for example 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7 parts, 2.8 parts, 2.9 parts, 3.0 parts, 3.1 parts, 3.2 parts, 3.3 parts, 3.4 parts, 3.5 parts, 3.6 parts, 3.7 parts, 3.8 parts, 3.9 parts, 4.0 parts, 5.1 parts, 5.2 parts, 5.3 parts, 5.4 parts, 5.5 parts, 5.6 parts, 5.7 parts, 5.8 parts, 5.9 parts, 6.0 parts, 6.1 parts, 6.2 parts, 6.3 parts, 6.4 parts, 6.5 parts, 6.6 parts, 6.7 parts, 6.8 parts, 6.9 parts, 7.0 parts, etc., preferably 0.1 to 5 parts by mass.

[0035] The γ-aminobutyric acid, zinc sulfate and adenine used in the present invention are all commercially available products, and can be selected as pure products or extracts or hydrates containing them. For example, zinc sulfate can be zinc sulfate heptahydrate.

[0036] In a specific embodiment of the present invention, the anti-aging composition includes other active ingredients and / or excipients acceptable in the field of cosmetics in addition to γ-aminobutyric acid, zinc sulfate and adenine. The other active ingredients may be active ingredients having at least one effect of whitening, moisturizing, anti-acne, anti-inflammatory, antibacterial, anti-aging, anti-oxidation, anti-wrinkle, etc. The excipients may be at least one of oils, solvents, surfactants, preservatives, antioxidants, moisturizers, pH regulators, functional additives, spices, pigments, etc.

[0037] The present invention also provides a method for preparing the anti-aging composition, which comprises mixing the components uniformly. The mixing method and order of the components are not limited.

[0038] The present invention also provides the use of the anti-aging composition in the preparation of a product that promotes collagen production, and the use thereof can be used as a raw material in the preparation of a product that promotes collagen production.

[0039] In a specific embodiment of the present invention, the collagen in the product for promoting collagen production includes various collagens beneficial to the human body, especially type III collagen.

[0040] In a specific embodiment of the present invention, the product that promotes collagen production includes skin care products, medicines or medical device products.

[0041] The present invention also provides the use of the anti-aging composition in the preparation of products for inhibiting fibroblast aging, and the use of the anti-aging composition can be used as a raw material in the preparation of products for inhibiting fibroblast aging.

[0042] In a specific embodiment of the present invention, the product that inhibits fibroblast aging includes skin care products, medicines or medical device products.

[0043] The present invention also provides a skin care product, comprising the anti-aging composition.

[0044] In a specific embodiment of the present invention, the content of γ-aminobutyric acid in the skin care product is 10-1000 mg / L, for example, 10 mg / L, 15 mg / L, 20 mg / L, 25 mg / L, 30 mg / L, 35 mg / L, 40 mg / L, 45 mg / L, 50 mg / L, 55 mg / L, 60 mg / L, 65 mg / L, 70 mg / L, 75 mg / L, 80 mg / L, 85 mg / L, 90 mg / L, 95 mg / L, 100 mg / L, 105 mg / L, 110 mg / L, 115 mg / L, 120 mg / L, 125 mg / L, 130 mg / L, 135 mg / L, 140 mg / L, 145 mg / L. / L, 150mg / L, 155mg / L, 160mg / L, 165mg / L, 170mg / L, 175mg / L, 180mg / L, 185mg / L, 190mg / L, 195mg / L, 200mg / L, 205mg / L, 210mg / L, 215mg / L, 220mg / L, 2 25mg / L, 230mg / L, 235mg / L, 240mg / L, 245mg / L, 250mg / L, 255mg / L, 260mg / L, 265mg / L, 270mg / L, 275mg / L, 280mg / L, 285mg / L, 290mg / L, 295mg / L, 300mg / L, 305mg / L, 310mg / L, 315mg / L, 320mg / L, 325mg / L, 330mg / L, 335mg / L, 340mg / L, 345mg / L, 350mg / L, 355mg / L, 360mg / L, 365mg / L, 370mg / L, 375mg / L, 38 0mg / L, 385mg / L, 390mg / L, 395mg / L, 400mg / L, 405mg / L, 410mg / L, 415mg / L, 420mg / L, 425mg / L, 430mg / L, 435mg / L, 440mg / L, 445mg / L, 450mg / L, 455mg / L , 460mg / L, 465mg / L, 470mg / L, 475mg / L, 480mg / L, 485mg / L, 490mg / L, 495mg / L, 500mg / L, 505mg / L, 510mg / L, 515mg / L, 520mg / L, 525mg / L, 530mg / L, 535 mg / L, 540mg / L, 545mg / L, 550mg / L, 555mg / L, 560mg / L, 565mg / L, 570mg / L, 575mg / L, 580mg / L, 585mg / L, 590mg / L, 595mg / L, 600mg / L, 605mg / L, 610mg / L,615mg / L, 620mg / L, 625mg / L, 630mg / L, 635mg / L, 640mg / L, 645mg / L, 650mg / L, 655mg / L, 660mg / L , 665mg / L, 670mg / L, 675mg / L, 680mg / L, 685mg / L, 690mg / L, 695mg / L, 700mg / L, 705mg / L, 710mg / L , 715mg / L, 720mg / L, 725mg / L, 730mg / L, 735mg / L, 740mg / L, 745mg / L, 750mg / L, 755mg / L, 760mg / L , 765mg / L, 770mg / L, 775mg / L, 780mg / L, 785mg / L, 790mg / L, 795mg / L, 800mg / L, 805mg / L, 810mg / L , 815mg / L, 820mg / L, 825mg / L, 830mg / L, 835mg / L, 840mg / L, 845mg / L, 850mg / L, 855mg / L, 860mg / L, 865mg / L, 870mg / L, 875mg / L, 880mg / L, 885mg / L, 890mg / L, 895mg / L, 900mg / L, 905mg / L, 910mg / L, 915mg / L, 920mg / L, 925mg / L, 930mg / L, 935mg / L, 940mg / L, 945mg / L, 950mg / L, 955mg / L, 960mg / L, 965mg / L, 970mg / L, 975mg / L, 980mg / L, 985mg / L, 990mg / L, 995mg / L, 1000mg / L, and any range between them.

[0045] In a specific embodiment of the present invention, the content of zinc sulfate in the skin care product is 0.1-10 mg / L, for example 0.1 mg / L, 0.2 mg / L, 0.3 mg / L, 0.4 mg / L, 0.5 mg / L, 0.6 mg / L, 0.7 mg / L, 0.8 mg / L, 0.9 mg / L, 1.0 mg / L, 1.1 mg / L, 1.2 mg / L, 1.3 mg / L, 1.4 mg / L, 1.5 mg / L, 1.6 mg / L, 1.7 mg / L, 1.8 mg / L, 1.9 mg / L, 2.0 mg / L, 2.1 mg / L, 2.2 mg / L, 2.3 mg / L, 2.4 mg / L, 2.5 mg / L, 2.6 mg / L, 2.7 mg / L, 2.8 mg / L, 2.9 mg / L, 3.0 mg / L, 3.1 mg / L, 3.2 mg / L, 3.3mg / L, 3.4 mg / L, 3.5mg / L, 3.6mg / L, 3.7 mg / L, 3.8 mg / L, 3.9 mg / L, 4.0 mg / L, 4.1 mg / L, 4.2 mg / L, 4.3mg / L, 4.4 mg / L, 4.5 mg / L, 4.6mg / L, 4.7 mg / L, 4.8 mg / L, 4.9 mg / L, 5.0 mg / L, 5.1 mg / L, 5.2mg / L, 5.3mg / L, 5.4 mg / L, 5.5 mg / L, 5.6mg / L, 5.7 mg / L, 5.8 mg / L, 5.9 mg / L, 6.0 mg / L, 6.1 mg / L, 6.2 mg / L, 6.3mg / L, 6.4 mg / L, 6.5 mg / L, 6.6mg / L, 6.7 mg / L, 6.8 mg / L, 6.9 mg / L, 7.0 mg / L, 7.1 mg / L, 7.2 mg / L, 7.3mg / L, 7.4 mg / L, 7.5 mg / L, 7.6mg / L, 7.7 mg / L, 7.8mg / L, 7.9 mg / L, 8.0 mg / L, 8.1 mg / L, 8.2 mg / L, 8.3mg / L, 8.4 mg / L, 8.5 mg / L, 8.6mg / L, 8.7 mg / L, 8.8 mg / L, 8.9 mg / L, 9.0 mg / L, 9.1 mg / L, 9.2 mg / L, 9.3mg / L, 9.4 mg / L, 9.5mg / L, 9.6mg / L, 9.7 mg / L, 9.8 mg / L, 9.9 mg / L, 10.0 mg / L.

[0046] In a specific embodiment of the present invention, the content of adenine in the skin care product is 0.1-10 mg / L, for example 0.1 mg / L, 0.2 mg / L, 0.3 mg / L, 0.4 mg / L, 0.5 mg / L, 0.6 mg / L, 0.7 mg / L, 0.8 mg / L, 0.9 mg / L, 1.0 mg / L, 1.1 mg / L, 1.2 mg / L, 1.3 mg / L, 1.4 mg / L, 1.5 mg / L, 1.6 mg / L, 1.7 mg / L, 1.8 mg / L, 1.9 mg / L, 2.0 mg / L, 2.1 mg / L, 2.2 mg / L, 2.3 mg / L, 2.4 mg / L, 2.5 mg / L, 2.6 mg / L, 2.7 mg / L, 2.8 mg / L, 2.9 mg / L, 3.0 mg / L, 3.1 mg / L, 3.2 mg / L, 3.3mg / L, 3.4 mg / L, 3.5mg / L, 3.6mg / L, 3.7 mg / L, 3.8 mg / L, 3.9 mg / L, 4.0 mg / L, 4.1 mg / L, 4.2 mg / L, 4.3mg / L, 4.4 mg / L, 4.5 mg / L, 4.6mg / L, 4.7 mg / L, 4.8 mg / L, 4.9 mg / L, 5.0 mg / L, 5.1 mg / L, 5.2mg / L, 5.3mg / L, 5.4 mg / L, 5.5 mg / L, 5.6mg / L, 5.7 mg / L, 5.8 mg / L, 5.9 mg / L, 6.0 mg / L, 6.1 mg / L, 6.2 mg / L, 6.3mg / L, 6.4 mg / L, 6.5 mg / L, 6.6mg / L, 6.7 mg / L, 6.8 mg / L, 6.9 mg / L, 7.0 mg / L, 7.1 mg / L, 7.2 mg / L, 7.3mg / L, 7.4 mg / L, 7.5 mg / L, 7.6mg / L, 7.7 mg / L, 7.8mg / L, 7.9 mg / L, 8.0 mg / L, 8.1 mg / L, 8.2 mg / L, 8.3mg / L, 8.4 mg / L, 8.5 mg / L, 8.6mg / L, 8.7 mg / L, 8.8 mg / L, 8.9 mg / L, 9.0 mg / L, 9.1 mg / L, 9.2 mg / L, 9.3mg / L, 9.4 mg / L, 9.5mg / L, 9.6mg / L, 9.7 mg / L, 9.8 mg / L, 9.9 mg / L, 10.0 mg / L.

[0047] In a specific embodiment of the present invention, the skin care product further comprises active ingredients and / or excipients acceptable in the field of skin care products. The other active ingredients may be active ingredients having at least one effect of whitening, moisturizing, anti-acne, anti-inflammatory, antibacterial, anti-aging, anti-oxidation, anti-wrinkle, etc. The excipients may be at least one of oils, solvents, surfactants, preservatives, antioxidants, moisturizers, pH regulators, functional additives, fragrances, pigments, etc.

[0048] Example

[0049] The present invention generally and / or specifically describes the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially. Among them, the sources of the raw materials described in the examples and comparative examples are shown in Table 1, the experimental reagents and cell lines used are shown in Table 2, and the experimental instruments used are shown in Table 3.

[0050]

[0051]

[0052]

[0053] Example 1

[0054] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed respectively, added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain an anti-aging composition. Among them, the content of γ-aminobutyric acid was 200 mg / L, the content of zinc sulfate was 0.06 mg / L, the content of adenine was 5 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 200:0.06:5.

[0055] Example 2

[0056] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain an anti-aging composition. Among them, the content of γ-aminobutyric acid was 200 mg / L, the content of zinc sulfate was 0.06 mg / L, the content of adenine was 0.1 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 200:0.06:0.1.

[0057] Example 3

[0058] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain an anti-aging composition. Among them, the content of γ-aminobutyric acid was 75 mg / L, the content of zinc sulfate was 0.17 mg / L, the content of adenine was 5 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 75:0.17:5.

[0059] Example 4

[0060] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain an anti-aging composition. Among them, the content of γ-aminobutyric acid was 50 mg / L, the content of zinc sulfate was 0.06 mg / L, the content of adenine was 0.3 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 50:0.06:0.3.

[0061] Example 5

[0062] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain an anti-aging composition. Among them, the content of γ-aminobutyric acid was 50 mg / L, the content of zinc sulfate was 0.17 mg / L, the content of adenine was 5 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 50:0.17:5.

[0063] Comparative Example 1

[0064] A certain amount of γ-aminobutyric acid was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of γ-aminobutyric acid was 50 mg / L.

[0065] Comparative Example 2

[0066] A certain amount of γ-aminobutyric acid was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of γ-aminobutyric acid was 75 mg / L.

[0067] Comparative Example 3

[0068] A certain amount of γ-aminobutyric acid was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of γ-aminobutyric acid was 200 mg / L.

[0069] Comparative Example 4

[0070] A certain amount of zinc sulfate heptahydrate was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of zinc sulfate was 0.06 mg / L.

[0071] Comparative Example 5

[0072] A certain amount of zinc sulfate heptahydrate was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of zinc sulfate was 0.17 mg / L.

[0073] Comparative Example 6

[0074] A certain amount of adenine was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of adenine was 0.1 mg / L.

[0075] Comparative Example 7

[0076] A certain amount of adenine was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of adenine was 0.3 mg / L.

[0077] Comparative Example 8

[0078] A certain amount of adenine was weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition, wherein the content of adenine was 5 mg / L.

[0079] Comparative Example 9

[0080] A certain amount of γ-aminobutyric acid, zinc sulfate heptahydrate, and adenine were weighed and added to a DMEM high-glucose medium containing 10% FBS, and mixed evenly to obtain a composition. The content of γ-aminobutyric acid was 500 mg / L, the content of zinc sulfate was 5.6 mg / L, the content of adenine was 10 mg / L, and the mass ratio of γ-aminobutyric acid, zinc sulfate, and adenine was 500:5.6:10.

[0081] Experimental Example 1 Effect on the Senescence of Human Fibroblasts

[0082] Experimental method: D-galactose induces HFF senescence

[0083] Experimental samples: compositions prepared in Examples 1-5 and Comparative Examples 1-9.

[0084] Blank control: DMEM high glucose medium containing 10% FBS.

[0085] The specific steps are as follows:

[0086] 1) Cell seeding: HFF cells were plated at 1×10 4 The cells / mL, 1 mL per well, were seeded in a 24-well plate and incubated overnight in an incubator (37°C, 5% CO2).

[0087] 2) Drug administration and culture: The blank control substance, the experimental samples of Examples 1-5 and Comparative Examples 1-9 were used for drug administration in groups, with 3 replicate wells set up in each group, 1 mL of sample was added to each well, and cultured in an incubator (37° C., 5% CO 2 ) for 48 hours.

[0088] 3) Inducing cell senescence: After 48 hours, fresh blank control substances, experimental samples of Examples 1-5 and Comparative Examples 1-9 were replaced to continue culturing the cells, and D-galactose was added to each well to a final concentration of 10 g / L to induce cell senescence.

[0089] 4) Senescent cell staining: After 72 hours of continuous culture, the samples were collected and stained with senescence-related β-galactosidase (SA-β-gal) using a cell senescence β-galactosidase staining kit to mark senescent cells. The specific staining steps are as follows:

[0090] ① Remove the culture medium from the wells, wash the cells once with PBS, add 1 mL of β-galactosidase staining fixative to each well, and fix at room temperature for 15 minutes;

[0091] ② Aspirate the staining fixative and wash the cells 3 times with PBS, 3 minutes each time;

[0092] ③ Aspirate PBS and add 1 mL of staining solution to each well (staining solution preparation method: β-galactosidase staining solution A: 10 μL; β-galactosidase staining solution B: 10 μL; β-galactosidase staining solution C: 930 μL; X-Gal solution: 50 μL);

[0093] ④Incubate in a 37°C oven overnight and wrap in aluminum foil to avoid light and evaporation;

[0094] ⑤ Remove the above staining working solution and add 1mL PBS to each well. Use Zeiss ordinary inverted microscope to take pictures.

[0095] 5) Analysis of staining results: Count the cells that are positive for SA-β-gal staining (blue), and calculate the SA-β-gal staining positive cell rate and SA-β-gal staining positive cell inhibition rate.

[0096] SA-β-gal staining positive cell rate = number of staining positive cells / total number of cells × 100%;

[0097] The inhibition rate of SA-β-gal staining positive cells = (the staining positive cell rate of blank control group - the staining positive cell rate of experimental group) / the staining positive cell rate of blank control group × 100%.

[0098] The experimental results are shown in Table 4 below:

[0099]

[0100] Note: The t-test was used for comparison among the groups. *P<0.05 indicated statistical difference, **P<0.01 indicated significant statistical difference, and ***P<0.001 indicated extremely significant statistical difference.

[0101] It can be seen from the above table that after adding the composition prepared in Examples 1-5, the inhibition rate of SA-β-gal staining positive cells was significantly improved, which was higher than that of Comparative Examples 1-9.

[0102] To illustrate that the components in the anti-aging composition provided by the present invention have a synergistic effect, rather than simply the sum of the effects of the components, we use the COLBY formula: E 理论 =X+Y+Z-(X*Y+X*Z+Y*Z) / 100+X*Y*Z / 10000 for verification, where X, Y, and Z are the inhibition rates of SA-β-gal positive cells treated with a single component, and E 理论 is the theoretical SA-β-gal positive cell inhibition rate after treatment with the composition, E 实际 is the actual SA-β-gal positive cell inhibition rate after treatment with the composition; E 实际 >E 理论 To enhance efficiency; E 实际 <E 理论 Antagonism; E 实际 =E 理论 For addition.

[0103] Among them, E in Example 1 理论 Based on the data of Comparative Examples 3, 4, and 8, the E of Example 2 is 理论 Based on the data of Comparative Examples 3, 4, and 6, the E of Example 3 is 理论 Based on the data of Comparative Examples 2, 5, and 8, the E of Example 4 is 理论 Based on the data of Comparative Examples 1, 4, and 7, the E of Example 5 is 理论 Calculated from the data of Comparative Examples 1, 5, and 8.

[0104] The results of the synergistic effect determination are shown in Table 5 below.

[0105]

[0106] As can be seen from Table 5, the E of Examples 1-5 实际 Both are greater than E 理论, indicating that the components in the anti-aging composition prepared by the present invention have a synergistic effect in inhibiting the aging of human fibroblasts.

[0107] Experimental Example 2 Effect on the Expression of Type III Collagen (COL3A1) Gene in Human Fibroblasts

[0108] Experimental method: Real-time quantitative polymerase chain reaction (RT-qPCR)

[0109] Experimental samples: compositions prepared in Example 3 and Comparative Examples 2, 5, and 8.

[0110] Blank control: DMEM high glucose medium containing 10% FBS.

[0111] The specific steps are as follows:

[0112] 1) Cell seeding: HFF cells were plated at 2×10 4 2 mL of cells / mL were plated in 6-well plates and incubated overnight in an incubator (37°C, 5% CO2).

[0113] 2) Drug administration and culture: The blank control substance, the experimental samples of Example 3 and Comparative Examples 2, 5 and 8 were used for drug administration in groups, with 3 replicate wells set up in each group, 2 mL of sample was added to each well, and the samples were collected after culturing in an incubator (37° C., 5% CO 2 ) for 72 hours.

[0114] 3) Extract RNA: Use FastPure® Cell / Tissue Total RNA Isolation Kit V2 reagent to extract RNA from each group of cells. The extraction operation is carried out at room temperature in a biological safety cabinet, using sterile, RNAse-free consumables. The steps are as follows:

[0115] ① Aspirate the supernatant of the cell culture medium and add 0.5 mL of Buffer RL to each well to digest and lyse the cells;

[0116] ② After observing that there are no obvious cell clusters, transfer the lysed samples to FastPure gDNA-Filter ColumnsⅢ and collect the filtrate after centrifugation at 12,000 rpm for 30 seconds;

[0117] ③ Add 0.25 mL of anhydrous ethanol to the filtrate, mix well and transfer to FastPure RNA Columns III. Centrifuge at 12,000 rpm for 30 sec and discard the filtrate.

[0118] ④ Add 0.7 mL of Buffer RW1 to FastPure RNA Columns III tube, centrifuge at 12,000 rpm for 30 sec, and discard the filtrate;

[0119] ⑤ Add 0.7 mL of Buffer RW2 to FastPure RNA Columns III tube, centrifuge at 12,000 rpm for 30 sec, and discard the filtrate;

[0120] ⑥ Add 0.5 mL of Buffer RW2 to FastPure RNA Columns III tube, centrifuge at 12,000 rpm for 2 min, transfer FastPure RNA Columns III to a collection tube, add 0.1 mL of RNase-free ddH2O, let stand at room temperature for 1 min, centrifuge at 12,000 rpm for 1 min, elute RNA and complete extraction;

[0121] ⑦ The extracted RNA was placed on ice and the absorbance was measured at 260nm / 280nm using an ELISA reader to detect the RNA purity and concentration.

[0122] 4) RNA reverse transcription: Use PrimeScript™ RT Reagent Kit with gDNA Eraser to reverse transcribe each group of extracted RNA into corresponding cDNA. The steps are as follows:

[0123] ① Prepare the genomic DNA removal reaction solution according to Table 6 below, mix well and let stand at room temperature for 5 minutes to remove the genomic DNA from the extracted RNA:

[0124]

[0125] ② Prepare the reverse transcription reaction solution according to Table 7 below, mix well and centrifuge the liquid to the bottom of the tube, and complete the reverse transcription reaction in the VeritiProPCR instrument running temperature program (37℃ 5min; 85℃ 5sec; 4℃ maintenance):

[0126]

[0127] 5) Real-time quantitative polymerase chain reaction (RT-qPCR): Completed on the QuantStudio3 RT-qPCR instrument using the TB Green® Premix Ex Taq™ kit. The steps are as follows:

[0128] ① According to Table 8, prepare PCR reaction solution, with 3 replicate wells in each group. The primer sequences used are as follows:

[0129] COL3A1 (forward: CGCCCTCCTAATGGTCAAGG-3; reverse: TTCTGAGGACCAGTAGGGCA);

[0130] Human beta actin (forward: GAGCATCCCCAAAGTTCACAA; revese: GTGGGGTGGCTTTTAGGATG).

[0131]

[0132] ② Mix the liquid and centrifuge to the bottom of the tube, and run the temperature program on the QuantStudio3 RT-qPCR instrument (first stage: 95°C, 30s, 1 cycle; second stage: 95°C, 5s, 60°C, 30s, 40 cycles; third stage: 95°C, 15s, 60°C, 1min, 1 cycle; 95°C, 15s, 1 cycle).

[0133] ③After the PCR reaction, the data of each group were normalized using β-Actin as the endogenous reference, and the expression level of type III collagen target gene RNA was determined by the 2-△△Ct method, and the expression level of type III collagen gene and the increase in type III collagen gene expression were calculated.

[0134] Type III collagen gene expression level = type III collagen RNA expression level in the experimental group / type III collagen RNA expression level in the blank control group*100%;

[0135] The increase in type III collagen gene expression = the type III collagen gene expression level in the experimental group - the type III collagen gene expression level in the blank control group.

[0136] After calculation, the experimental results are shown in Table 9.

[0137]

[0138] Note: The t-test was used for comparison among the groups. *P<0.05 indicated statistical difference, **P<0.01 indicated significant statistical difference, and ***P<0.001 indicated extremely significant statistical difference.

[0139] It can be seen from Table 9 that the composition prepared in Example 3 can significantly improve the expression of collagen. We also use the COLBY formula to verify the synergistic effect of the composition. The COLBY formula and the synergistic effect judgment method are as described in Experimental Example 1. The verification results are shown in Table 10:

[0140]

[0141] It can be seen from Table 10 that the E 实际 Greater than E 理论, indicating that the components in the anti-aging composition prepared by the present invention have a synergistic effect in promoting collagen expression.

[0142] Experimental Example 3 Effects on the Expression of Collagen in Human Fibroblasts

[0143] Experimental method: Cell immunofluorescence staining

[0144] Experimental sample: Example 3.

[0145] Blank control: DMEM high glucose medium containing 10% FBS.

[0146] The specific steps are as follows:

[0147] 1) Cell seeding: HFF cells were plated at 2×10 4 1 mL of cells / mL were plated in a 24-well plate and incubated overnight in an incubator (37°C, 5% CO2).

[0148] 2) Drug administration and culture: blank control substance and the experimental samples of Example 3 were used for drug administration in groups, with 3 replicate wells set up in each group. 1 mL of sample was added to each well, and the samples were collected after culturing in an incubator (37° C., 5% CO 2 ) for 72 hours.

[0149] 3) Immunofluorescence staining: Perform immunofluorescence staining on each group of cells according to the following steps:

[0150] ① Cell fixation: Add 1 mL of 4% paraformaldehyde solution to each well to fix the sample for 15 minutes, and wash the sample three times with PBS solution;

[0151] ② Cell blocking: Add 1 mL of 1% BSA solution to each well and block the sample at 37°C for 2 hours. After incubation, wash the sample 3 times with PBST solution.

[0152] ③ Primary antibody incubation: Add 0.5 mL of 1% BSA solution to each well, and add 1 μL of type III collagen antibody (COL3A1 (E3K9U) Rabbit mAb, 1:500 dilution), incubate overnight at 4°C, and wash the samples three times with PBST solution after incubation.

[0153] ④ Fluorescent secondary antibody incubation and Phalloidin-iFluor 594 staining: Add 0.5mL 1% BSA solution to each well, and add 0.5μL fluorescent secondary antibody (goat anti-rabbit IgG H&L Alexa Fluor® 488, 1:1000 dilution) and 0.5μL Phalloidin-iFluor 594 (1:1000 dilution), and incubate in a 37°C incubator in the dark for 2 hours. After staining, wash the sample 3 times with PBST solution.

[0154] ⑤DAPI nuclear staining: Add 0.5 mL of PBS solution containing 2 μg / mL DAPI to each well and incubate in a 37°C incubator in the dark for 15 minutes for staining. After staining, wash the sample 3 times with PBS solution.

[0155] ⑥After all staining is completed, use a fluorescence microscope to detect the fluorescence signal in the corresponding channel.

[0156] The experimental results are as follows Figure 1 As shown, the first column is human fibroblasts cultured using a blank control group, and the second column is human fibroblasts cultured using Example 3; the first row is a picture of the green fluorescence channel after staining, and the second row is a picture of the integration of three channels (red is Phalloidin-iFluor 594 stained for the cytoskeleton, blue is DAPI stained for the nucleus and cytoplasm, and green is fluorescently stained type III collagen. Cell localization can be seen through the channel integration picture). It can be seen from the figure that the green fluorescence of type III collagen represented by Example 3 is significantly improved compared with the blank control group, indicating that each component in the anti-aging composition prepared by the present invention can promote the expression of type III collagen.

[0157] The above is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment according to the technical essence of the present invention without departing from the technical solution of the present invention still belongs to the protection scope of the technical solution of the present invention.

Claims

1. An anti-aging composition, It is characterized in that The invention comprises gamma-aminobutyric acid, zinc sulfate and adenine, wherein the mass ratio of the gamma-aminobutyric acid, zinc sulfate and adenine is 40-220:0.04-0.25:0.08-7.

2. The anti-aging composition according to claim 1, It is characterized in that The mass ratio of the gamma-aminobutyric acid, zinc sulfate and adenine is 50-200: 0.05-0.2: 0.1-5.

3. Use of the anti-aging composition according to claim 1 or 2 in the preparation of a product for promoting collagen production.

4. The use according to claim 3, It is characterized in that The collagen includes type III collagen.

5. The use according to claim 3 or 4, It is characterized in that The products that promote collagen production include skin care products, medicines or medical device products.

6. Use of the anti-aging composition according to claim 1 or 2 in the preparation of a product for inhibiting fibroblast aging.

7. The use according to claim 6, It is characterized in that The products that inhibit fibroblast aging include skin care products, medicines or medical device products.

8. A skin care product, It is characterized in that The anti-aging composition comprises the anti-aging composition according to claim 1 or 2.

9. The skin care product according to claim 8, It is characterized in that Include at least one of the following conditions: Condition 1: The content of γ-aminobutyric acid in the skin care product is 10 to 1000 mg / L; Condition 2: The content of zinc sulfate in the skin care product is 0.1-10 mg / L; Condition 3: The content of adenine in the skin care product is 0.1-10 mg / L; Condition 4: The skin care product also includes active ingredients and / or excipients acceptable in the field of skin care products.

Citation Information

Patent Citations

  • Composition of probiotics and sodium hyaluronate and application thereof

    CN114470005A

  • Stable anti-aging and whitening composition as well as preparation method and application thereof

    CN114515253A

  • Composition for lightening skin wrinkles and application thereof

    CN114681368A

  • Composition containing gamma-aminobutyric acid and alkaline probiotic active peptide and application of composition in preparation of product with anti-aging effect

    CN116987142A

  • Preparation method and use for purine compounds double amino acid ester

    CN101033238A